There may be a future for cardiac myosin inhibitors in heart failure with preserved ejection fraction (HFpEF), according to the proof-of-concept EMBARK-HFpEF trial. An established cardiac myosin ...
The Heart Failure Society of America (HFSA), the Heart Failure Association of the European Society of Cardiology (HFA of the ESC), and the Japanese Heart Failure Society (JHFS) announced today a new ...
Heart failure is a heterogeneous syndrome. Approximately 30–50% of patients with heart failure have normal or near normal left ventricle function. Several epidemiological studies confirm that the ...
A tradition at the HFSA meetings, the Hyde Park sessions give presenters, "unfettered by the usual standards of peer review," a chance to present or stimulate ideas that "may or may not be supported ...
Background There is a lack of contemporary data describing patients with left ventricular (LV) systolic dysfunction post ...
Panelists discuss how ARNIs like sacubitril-valsartan provide superior outcomes compared with ACE inhibitors in HFrEF (20% reduction in cardiovascular events, 16% mortality reduction), with broad FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results